ADC Therapeutics (ADCT) Return on Sales (2023 - 2026)

ADC Therapeutics' (ADCT) quarterly Return on Sales came in at 0.02% in Q1 2026, up 6.0% year-on-year from 0.02% in Q1 2025, and up 36.73% quarter-over-quarter from 0.03% in Q3 2025.

ADC Therapeutics (ADCT) Return on Sales (2023 - 2026) Analysis & Trends

ADC Therapeutics has disclosed Return on Sales across 4 years of filings, most recently posting 0.02% for Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Alterity Therapeutics 762,369.55 Bn 762,369.51 Bn - -
2 Belite Bio 55,096.00 Bn 55,096.00 Bn - -
3 Quantum Biopharma 17,755.80 Bn 17,755.79 Bn - -
4 Legend Biotech 3,486.00 Bn 3,485.71 Bn 242.10 Mn 0.00%
5 Akari Therapeutics 1,737.42 Bn 1,737.41 Bn - -
6 Evaxion A 1,551.28 Bn 1,551.26 Bn - 0.00%
7 Psyence Biomedical 227.32 Bn 227.31 Bn - -
8 Vertex Pharmaceuticals 110.84 Bn 103.59 Bn 2.59 Bn 0.00%
9 Abivax 91.71 Bn 91.71 Bn - -
10 ADC Therapeutics 167.24 Mn -63.76 Mn 7.33 Mn -0.02%

Historic Data

Download Data
DateValue
Mar 31, 2026 -0.02%
Sep 30, 2025 -0.03%
Jun 30, 2025 -0.03%
Mar 31, 2025 -0.08%
Sep 30, 2024 -0.02%
Jun 30, 2024 -0.02%
Mar 31, 2024 -0.03%
Sep 30, 2023 -0.03%
Jun 30, 2023 -0.02%